Core Points - The Sci-Tech ETF (588050) opened down 1.01% at 1.369 yuan on December 15 [1] - Major holdings in the ETF include companies like SMIC, Haiguang Information, and Cambrian, with varying performance; SMIC down 1.41%, Haiguang down 1.05%, and Cambrian down 2.08% [1] - The ETF's performance benchmark is the Shanghai Stock Exchange Sci-Tech 50 Index, managed by ICBC Credit Suisse Asset Management, with a fund manager named Zhao Xu [1] - Since its establishment on September 28, 2020, the ETF has returned -3.35%, with a one-month return of -2.02% [1] Company Performance - SMIC opened down 1.41% [1] - Haiguang Information opened down 1.05% [1] - Cambrian opened down 2.08% [1] - Lanke Technology opened down 2.02% [1] - Zhongwei Company opened up 0.16% [1] - United Imaging opened down 0.14% [1] - Kingsoft Office opened down 1.27% [1] - Chipone Technology opened down 5.06% [1] - Stone Technology opened down 0.99% [1] - Transsion Holdings opened down 0.45% [1]

Group 1 - The company, Jianxin Superconductor, is set to issue shares at a price of 18.58 yuan, with a total market value of 2.337 billion yuan and an issuance price-to-earnings ratio of 61.97 [2] - The main business of the company includes the production of medical magnetic resonance imaging (MRI) equipment, superconducting magnets, and gradient coils, making it the largest producer of medical MRI superconducting magnets globally with a market share of 4.2% [2][3] - The company's revenue composition is primarily from superconducting products (73.17%) and permanent magnet products (26.83%) [2] Group 2 - The company has been involved in the development of non-evaporative superconducting magnets since 2015, breaking the long-standing monopoly of European, American, and Japanese manufacturers [3] - The company is focused on the research and production of next-generation liquid helium-free superconducting magnets and 1.5T large aperture liquid helium-free superconducting magnets [3] - In the past three years, the company's net profit has been 425 million yuan, with a projected revenue of 451 million yuan in 2023, reflecting a growth of 25.55% [3]

Core Insights - Zhongbao Investment has established itself as a significant player in the insurance fund management sector, managing over 450 billion yuan and focusing on long-term investments and strategic asset management [1][3][6] Group 1: Investment Strategy - The company emphasizes alternative investments and plans to expand into secondary and overseas markets to align with national strategies [1][3] - Zhongbao Investment has supported various technology companies, including domestic GPU firms, by providing substantial funding, showcasing the synergy between insurance capital and technological innovation [2][3] - The firm has developed a diverse toolbox of investment products, including equity and debt instruments, to effectively deploy long-term capital into strategic emerging industries [3][6] Group 2: Social Responsibility and Urban Development - Zhongbao Investment has actively participated in urban renewal projects, contributing 20 billion yuan to support the renovation of old residential areas in Shanghai, which has leveraged an additional 80 billion yuan in loans and social capital [4][5] - The company has also engaged in rural revitalization efforts, ensuring sustainable economic development in local communities after completing poverty alleviation tasks [11] Group 3: Future Development and Governance - The company is set to transition under the supervision of the Shanghai State-owned Assets Supervision and Administration Commission by 2025, aiming to enhance its governance and operational efficiency [10] - Zhongbao Investment has outlined a new development strategy focusing on comprehensive asset management, risk management, and international expansion, positioning itself as a leader in the new financial landscape [8][10]

Core Viewpoint - The company Jianxin Superconductor (688805.SH) is set to be available for subscription on the Sci-Tech Innovation Board, focusing on the research, production, and sales of core components for medical MRI equipment, which constitute approximately 50% of the cost of MRI devices [1][6]. Group 1: Company Overview - Jianxin Superconductor was established on December 11, 2013, and is one of the earliest manufacturers in China to produce high-field superconducting magnets on a large scale [6]. - The company has developed a diverse product matrix, including 1.5T zero-evaporation superconducting magnets and 3.0T zero-evaporation superconducting magnets, becoming the largest independent supplier of superconducting magnets globally [6]. - Jianxin Superconductor has established close partnerships with renowned MRI equipment manufacturers such as Fujifilm, GE Healthcare, and others, with over 50% of its products being sold to international markets [6]. Group 2: Financial Information - The initial offering price is set at 18.58 yuan per share, with an institutional quotation of 18.89 yuan per share, and the company's market capitalization is approximately 2.337 billion yuan [3]. - The company’s projected earnings per share (PE) ratio is 61.97, compared to the industry average of 31.79 [3]. - The company plans to invest approximately 2.75 billion yuan in a project to produce 600 sets of non-liquid helium superconducting magnets, which accounts for 35.48% of the total fundraising [5]. Group 3: Risks and Challenges - The company faces a high customer concentration risk, with the top five customers accounting for 73.75% to 83.43% of total revenue from 2022 to the first half of 2025, with Fujifilm being the largest customer [7]. - Although sales and gross profit from Fujifilm do not exceed 50%, any significant changes in the customer landscape or performance could adversely affect the company's profitability [7].

智通财经APP获悉，12月15日，健信超导(688805.SH)开启申购，发行价格为18.58元/股，申购上限为1万股，市盈率 61.97倍，属于上交所，广发证券为其保荐人。 据招股书，公司主要从事医用磁共振成像(MRI)设备核心部件的研发、生产和销售，主要产品包括超导磁体、永磁体和 梯度线圈，占MRI设备核心部件成本的比例在50%左右。公司通过自主研发和持续创新推动磁共振的迭代进步及推广 普及。公司在超导磁体、永磁体和梯度线圈上突破核心技术并实现规模化制造，保障了国产磁共振产业核心部件自主 可控，支撑并推动了国产超导磁共振产业的快速发展，降低医院磁共振检查的价格。 在超导领域，公司已形成包括1.5T零挥发超导磁体、1.5T无液氦超导磁体、3.0T零挥发超导磁体和开放式零挥发超导磁 体在内的丰富产品矩阵，成为全球磁共振行业内排名第一的超导磁体独立供应商。在零挥发超导技术领域，公司追平 了与国际巨头约20年的技术差距，并通过设计和工艺创新持续提升产品性能水平和成本竞争力。公司是国内最早规模 化生产高场强超导磁体的厂商之一，2015年以来，在零挥发超导磁体特别是1.5T产品领域与联影医疗等同步打破了欧 美、日本厂 ...

Core Viewpoint - The company Jianxin Superconductor (688805.SH) has initiated its subscription with an issue price of 18.58 yuan per share and a price-to-earnings ratio of 61.97 times, focusing on the research, production, and sales of core components for MRI equipment, which account for approximately 50% of the cost of MRI devices [1]. Group 1: Company Overview - The company specializes in the research, production, and sales of core components for medical MRI equipment, including superconducting magnets, permanent magnets, and gradient coils [1]. - The company has achieved breakthroughs in core technologies for superconducting magnets, permanent magnets, and gradient coils, ensuring the independence and controllability of core components in the domestic MRI industry [2]. Group 2: Product Development and Market Position - The company has developed a comprehensive product matrix in the superconducting field, including 1.5T and 3.0T zero-evaporation superconducting magnets, becoming the world's leading independent supplier of superconducting magnets [2]. - The company has closed a 20-year technology gap with international giants in zero-evaporation superconducting technology and has broken the long-standing monopoly of European, American, and Japanese manufacturers in the 1.5T product field since 2015 [2]. Group 3: Technological Advancements - The company has transitioned from a follower to a leader in the next-generation helium-free superconducting technology, achieving a fully helium-free superconducting magnet and being recognized as the "international first set of equipment" by the Zhejiang Provincial Economic and Information Technology Department in 2021 [3]. - The company is the largest supplier of MRI permanent magnets globally, providing high-quality products that are economically viable and suitable for grassroots medical systems [3]. Group 4: Financial Performance - The company reported revenues of approximately 359 million yuan, 451 million yuan, 425 million yuan, and 252 million yuan for the years 2022, 2023, 2024, and the first half of 2025, respectively, with net profits of 34.63 million yuan, 48.73 million yuan, 55.78 million yuan, and 31.92 million yuan during the same periods [4]. - As of June 30, 2025, the total assets of the company were approximately 688.99 million yuan, with a debt-to-asset ratio of 29.22% [5].

12月15日，可申购科创板的健信超导（688805.SH）。该公司成立于2013年12月11日，主要从事医用磁 共振成像（MRI）设备核心部件的研发、生产和销售，主要产品包括超导磁体、永磁体和梯度线圈，这 三大类部件占MRI设备核心部件成本的比例在50%左右。 打新早知道 Est Un Descrip | 今日申购 | | | | | --- | --- | --- | --- | | 688805.SH 健信超导 | | | | | 发行价(元/股) | 机构报价(元/股) | 市值(亿元) | 所属行业 | | 18.58 | 18.89 | 23.37 | 医疗仪器设备及器 | | | | | 械制造 | | 发行市盈率 | 行业市盈率 | 可比公司 | 可比公司动态市盈率 | | 61.97 | 31.79 | 联影医疗 | 61.96 亏损 | | | | 展光图疗 | | | | | 奕瑞科技 | 38.94 | | 业绩情况 | | | | 50% 5.0 4.5 40% 4.0 3.5 30% 3.0 20% 2.5 2.0 10% 1.5 1.0 0% 0.5 -10% 0.0 2022年 ...

路演嘉宾合影 健信超导：持续自主研发创新努力成为全球磁共振核心部件行业领导品牌 ——宁波健信超导科技股份有限公司首次公开发行股票并在科创板上市网上投资者交流会精彩回放 问：公司的主营业务是什么？ 许建益：公司主要从事医用磁共振成像（MRI）设备核心部件的研发、生产和销售，主要产品包括超导 磁体、永磁体和梯度线圈。公司以"让磁共振成为老百姓用得起的日常诊查手段"为使命，通过自主研发 和持续创新，推动磁共振技术迭代进步及推广普及。 出席嘉宾 宁波健信超导科技股份有限公司董事长许建益先生 宁波健信超导科技股份有限公司董事、总经理姚海锋先生 宁波健信超导科技股份有限公司董事、副总经理、董事会秘书许卉女士 宁波健信超导科技股份有限公司财务总监叶来刚先生 广发证券股份有限公司投行业务管理委员会委员、董事总经理袁海峰先生 广发证券股份有限公司保荐代表人周寅先生 广发证券股份有限公司保荐代表人王振先生 经营篇 问：请介绍公司的产品矩阵。 许建益：公司已形成包括1.5T零挥发超导磁体、1.5T无液氦超导磁体、3.0T零挥发超导磁体和开放式零 挥发超导磁体在内的丰富产品矩阵，成为全球排名第一的超导磁体独立供应商。在零挥发超导技术 ...

Core Insights - The article highlights the role of China Insurance Investment Co., Ltd. (中保投资) as a significant player in the long-term investment landscape, particularly in supporting technological innovation and urban renewal projects in China [5][9][10]. Group 1: Company Overview - 中保投资 has managed over 450 billion yuan in assets, positioning itself as a key force in the long-term investment and patient capital sectors in China [5]. - The company has focused on alternative investments over the past decade and aims to expand its presence in secondary and overseas markets [6]. Group 2: Investment in Technology - The recent listing of domestic GPU companies, such as 摩尔线程, marks a significant moment for China's tech sector, with 中保投资 playing a crucial role in supporting these firms [7]. - 中保投资 has invested in various domestic GPU enterprises, demonstrating its commitment to fostering innovation in the technology sector [8]. Group 3: Urban Renewal Initiatives - 中保投资 has committed 20 billion yuan to support urban renewal projects in Shanghai, leveraging its investment to attract an additional 80 billion yuan from bank loans and social capital [9]. - The company has also provided 5 billion yuan in funding for urban village renovation projects, contributing to significant improvements in urban quality and functionality [9]. Group 4: Strategic Partnerships and Future Plans - 中保投资 has established partnerships to create funds aimed at supporting the semiconductor industry, reflecting its strategic focus on emerging sectors [8]. - The company plans to enhance its investment strategies by adopting a comprehensive approach that includes asset management and investment, aiming to align with national development strategies [12]. Group 5: Governance and Social Responsibility - 中保投资 has seen its net assets grow over three times in the past decade, emphasizing the importance of political leadership in driving high-quality development [13]. - The company is committed to social responsibility, having successfully completed poverty alleviation efforts and now focusing on rural revitalization initiatives [15].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].